Sonia Jaramillo

Sonia Jaramillo

Auto-generated profile, based on publicly available information

Sonia Jaramillo

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2020 in eJHaem
Verified
Journal Article
Open access
PDF file
SJSonia Jaramillo
Sonia Jaramillo
HHHannah Hennemann
Hannah Hennemann
PHPeter Horak
Peter Horak
VTVeronica Teleanu
Veronica Teleanu
CHChristoph E. Heilig
Christoph E. Heilig
RSRichard F. Schlenk
Richard F. Schlenk
T‐cell acute lymphoblastic leukemia (T‐ALL) is a rare, aggressive T‐cell malignancy. Chemotherapy alone cures only 25‐45% of the cases, thus, novel treatment agents and strategies are urgently needed. We assessed the efficacy of ruxolitinib in a patient with a cutaneous relapse after allogeneic blood cell transplantation of a refractory T‐ALL with a Janus kinase 3 (JAK3) mutation. In this case report, we were able to show the potential benefit of the JAK inhibitor ruxolitinib in JAK3‐mutated refractory T‐ALL and emphasize the importance of integrating molecular markers in current treatment decision making for patients with T‐ALL.

3 November 2021 in Trials
Verified
Journal Article
Open access
PDF file
SJSonia Jaramillo
Sonia Jaramillo
JKJohannes Krisam
Johannes Krisam
LCLucian Le Cornet
Lucian Le Cornet
MKMarkus Kratzmann
Markus Kratzmann
LBLukas Baumann
Lukas Baumann
RSRichard F. Schlenk
Richard F. Schlenk
Background: Overall survival remains poor in older patients with acute myeloid leukemia (AML) with less than 10% being alive after 5 years. In recent studies, a significant improvement in event-free, relapse-free and overall survival was shown by adding gemtuzumab ozogamicin (GO), a humanized antibody-drug conjugate directed against CD33, to intensive induction therapy once or in a sequential dosing schedule. Glasdegib, the small-molecule inhibitor of smoothened (SMO), also showed improved overall survival in patients not eligible for intensive chemotherapy when combined with low-dose cytarabine compared to low-dose cytarabine alone. These findings warrant further investigations in the phase III GnG trial. Methods/Design: This is a randomized phase III trial with measurable residual disease (MRD) after induction therapy and event-free survival (EFS) as primary endpoints. The two research questions are addressed in a 2 by 2 factorial design. Patients age 60 years and older are upfront randomized 1:1 in one of the two induction arms: GO administered to intensive induction therapy on days 1,4, and 7 versus GO administered once on day 1 (GO-147 versus GO-1), and double-blinded 1:1 in one of the subsequent treatment arms glasdegib vs. placebo as adjunct to consolidation therapy and as single-agent maintenance therapy for six months. Chemotherapy backbone for induction therapy consists of standard 7 + 3 schedule with cytarabine 200 mg/m2 continuously days 1 to 7, daunorubicin 60 mg/m2 days 1, 2, and 3 and high-dose cytarabine (1 g/m2, bi-daily, days 1, 2, and 3) for consolidation therapy. Addressing two primary endpoints, MRD-negativity after induction therapy and event-free survival (EFS), 252 evaluable patients are needed to reject each of the two null hypotheses at a two-sided significance level of 2.5% with a power of at least 85%. Ethics and dissemination: Ethical approval and approvals from the local and federal competent authorities were granted. Trial results will be reported via peer-reviewed journals and presented at conferences and scientific meetings. Trial status: Protocol version: 1st version 20.10.2020, no amendments yet. Study initiation on February 16, 2021. First patient was recruited on April 1st. Trial registration: ClinicalTrials.gov NCT04093505; EudraCT 2019-003913-32. Registered on October 30, 2018.

16 July 2021 in Current Oncology Reports
Verified
Journal Article
Open access
PDF file
SJSonia Jaramillo
Sonia Jaramillo
RSRichard F. Schlenk
Richard F. Schlenk
Purpose of Review: Until recently, improvement in terms of survival for patients with acute myeloid leukemia (AML) was achieved mostly in younger patients with dose intensification of conventional chemotherapy and a broadening use of allogeneic hematopoietic cell transplantation (allo-HCT) whereas the results remained dismal and very stable in patients older than 60 years. The current review highlights the recent developments in standard intensive post-remission chemotherapy, evidence for the use of recently approved agents, and discusses the relevance of measurable residual disease (MRD) measurement in treatment adaptation. Recent Findings: Current approvals of midostaurin, venetoclax, gemtuzumab ozogamicin, VYXEOS, ivosidenib, enasidenib, glasdegib, and CC-486 have changed the structure, aim, and schedule of consolidation therapy, and new, well-tolerated agents are being evaluated as maintenance therapies. Furthermore, MRD assessment has been implemented to guide the duration and type of consolidation and maintenance therapy as well as indicate the optimal timing of allo-HCT. Summary: Novel therapies have changed the structure and perspective of post-remission therapy in AML for both young and elderly patients. In addition, MRD assessment could guide the type, duration, and intensity of consolidation and maintenance therapy.

15 September 2023 in Trials
Verified
Journal Article
Open access
PDF file
SJSonia Jaramillo
Sonia Jaramillo
LCLucian Le Cornet
Lucian Le Cornet
MKMarkus Kratzmann
Markus Kratzmann
JKJohannes Krisam
Johannes Krisam
MGMartin Görner
Martin Görner
RSRichard F. Schlenk
Richard F. Schlenk
Background: About 50% of older patients with acute myeloid leukemia (AML) fail to attain complete remission (CR) following cytarabine plus anthracycline-based induction therapy. Salvage chemotherapy regimens are based on high-dose cytarabine (HiDAC), which is frequently combined with mitoxantrone (HAM regimen). However, CR rates remain low, with less than one-third of the patients achieving a CR. FLT3-ITD has consistently been identified as an unfavorable molecular marker in both relapsed and refractory (r/r)-AML. One-quarter of patients who received midostaurin are refractory to induction therapy and relapse rate at 2 years exceeds 40%. The oral second-generation bis-aryl urea tyrosine kinase inhibitor quizartinib is a very selective FLT3 inhibitor, has a high capacity for sustained FLT3 inhibition, and has an acceptable toxicity profile. Methods: In this multicenter, upfront randomized phase II trial, all patients receive quizartinib combined with HAM (cytarabine 3g/m2 bidaily day one to day three, mitoxantrone 10mg/m2 days two and three) during salvage therapy. Efficacy is assessed by comparison to historical controls based on the matched threshold crossing approach with achievement of CR, complete remission with incomplete hematologic recovery (CRi), or complete remission with partial recovery of peripheral blood counts (CRh) as primary endpoint. During consolidation therapy (chemotherapy and allogeneic hematopoietic cell transplantation), patients receive either prophylactic quizartinib therapy or measurable residual disease (MRD)-triggered preemptive continuation therapy with quizartinib according to up-front randomization. The matched threshold crossing approach is a novel study-design to enhance the classic single-arm trial design by including matched historical controls from previous clinical studies. It overcomes common disadvantages of single-armed and small randomized studies, since the expected outcome of the observed study population can be adjusted based on the matched controls with a comparable distribution of known prognostic and predictive factors. Furthermore, balanced treatment groups lead to stable statistical models. However, one of the limitations of our study is the inability to adjust for unobserved or unknown confounders. Addressing the primary endpoint, CR/CRi/CRh after salvage therapy, the maximal sample size of 80 patients is assessed generating a desirable power of the used adaptive design, assuming a logistic regression is performed at a one-sided significance level α=0.05, the aspired power is 0.8, and the number of matching partners per intervention patient is at least 1. After enrolling 20 patients, the trial sample size will be recalculated in an interim analysis based on a conditional power argument. Conclusion: Currently, there is no commonly accepted standard for salvage chemotherapy treatment. The objective of the salvage therapy is to reduce leukemic burden, achieve the best possible remission, and perform a hemopoietic stem-cell transplantation. Thus, in patients with FLT3-ITD mutation, the comparison of quizartinib with intensive salvage therapy versus chemotherapy alone appears as a logical consequence in terms of efficacy and safety. Ethics and dissemination: Ethical approval and approvals from the local and federal competent authorities were granted. Trial results will be reported via peer-reviewed journals and presented at conferences and scientific meetings. Trial registration: ClinicalTrials.gov NCT03989713; EudraCT Number: 2018-002675-17.

14 April 2026 in Blood
Verified
Journal Article
Open access
ECEnise Ceran
Enise Ceran
SJSonia Jaramillo
Sonia Jaramillo
AMAnne Kathrin Merbach
Anne Kathrin Merbach
CRChristian Rohde
Christian Rohde
MWMaxi Wass
Maxi Wass
CMCarsten Müller-Tidow
Carsten Müller-Tidow
Relapse after remission remains the primary cause of treatment failure in acute myeloid leukemia (AML), underscoring the need for strategies to eliminate residual leukemic cells. The bone marrow microenvironment, largely orchestrated by the CXCR4-CXCL12 axis, enables leukemia cell survival and chemoresistance by anchoring blasts in their protective bone marrow niche. Motixafortide, a selective CXCR4 antagonist, mobilizes leukemic cells and disrupts tumor-microenvironment interactions in preclinical models. In this randomized, double-blind, placebo-controlled phase II trial (NCT02502968; registered at ClinicalTrials.gov), 128 patients in first remission received high‑dose cytarabine (HiDAC) plus Motixafortide or placebo. Median relapse-free survival (RFS) did not substantially differ between groups: 10.3 months (95% CI, 8.0-12.0) for Motixafortide and 11.5 months (95% CI, 8.6-24.1) for placebo (log-rank p=0.98). But scMRD analysis, performed before consolidation, demonstrated heterogeneity of CXCR4 inhibition benefit: in the placebo group, higher CXCR4 expression was associated with increased relapse risk (p=0.02), whereas in the Motixafortide group, higher CXCR4 expression was linked to a reduced relapse rate (p=0.047). Exploratory analyses identified scMRD levels at which higher MRD burden was associated with inferior overall survival (OS). Taken together, combining functional MRD profiling with biomarker-driven patient selection, such as CXCR4 expression, may enable more precise and effective post-remission interventions in AML. This clinical trial is registered at EudraCT number: 2014-002702-21

16 June 2022 in Research Square
Verified
Preprint
Open access
PDF file
SJSonia Jaramillo
Sonia Jaramillo
LCLucian Le Cornet
Lucian Le Cornet
MKMarkus Kratzmann
Markus Kratzmann
JKJohannes Krisam
Johannes Krisam
MGMartin Görner
Martin Görner
RSRichard F. Schlenk
Richard F. Schlenk
Background: About 50% of older patients with acute myeloid leukemia (AML) fail to attain complete remission (CR) following cytarabine plus anthracycline-based induction therapy. Salvage chemotherapy regimens are based on high dose cytarabine (HiDAC), which is frequently combined with mitoxantrone (HAM regimen). However, CR rates remain low, with less than one-third of the patients achieving a CR. FLT3 -ITD has consistently been identified as an unfavorable molecular marker in both relapsed and refractory (r/r)-AML. One-quarter of patients who received midostaurin are refractory to induction therapy and relapse rate at two years exceeds 40%. The oral second-generation bis-aryl urea tyrosine kinase inhibitor quizartinib, is a very selective FLT3 inhibitor, has a high capacity for sustained FLT3 inhibition, and an acceptable toxicity profile. Methods: In this multicenter, upfront randomized phase II trial, all patients receive quizartinib combined with HAM (cytarabine 3g/m² bidaily day one to day three, mitoxantrone 10mg/m² days two and three) during salvage therapy. Efficacy is assessed by comparison to historical controls based on the matched threshold crossing approach with achievement of CR or complete remission with incomplete hematologic recovery (CRi) as primary endpoints. During consolidation therapy (chemotherapy and allogeneic hematopoietic cell transplantation), patients receive either prophylactic quizartinib therapy or measurable residual disease (MRD)-triggered preemptive continuation therapy with quizartinib according to up-front randomization. Addressing the primary endpoint, CR/ CRi, after salvage therapy, the sample size required is of maximum 80 patients, assuming a logistic regression is performed at a one-sided significance level α=0.05, the aspired power is 0.8, and the number of matching partners per intervention patient is at least 1. After enrolling 30 patients, the trial sample size will be recalculated in an interim analysis based on a conditional power argument.Ethics and Dissemination: Ethical approval and approvals from the local and federal competent authorities were granted. Trial results will be reported via peer-reviewed journals and presented at conferences and scientific meetings. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT03989713; EudraCT Number: 2018-002675-17. KEYWORDS (LIMIT: 3-10): Quizartinib, relapse, refractory, acute myeloid leukemia, measurable residual disease. matched threshold crossing approach